ORG-43902 (ORG-41841) is a thienopyrimidine-class small molecule, orally active biased partial agonist at the CG receptor. It activates Leydig cells to produce testosterone without injecting a protein hormone. The mechanistic case for preferring it over hCG is real.
LH and hCG engage LHCGR’s N-terminal exodomain; ORG-43902 binds an allosteric pocket in the transmembrane endodomain instead, which produces different downstream coupling [@vanKoppenSignalingSelectiveNanomolar2008]. hCG drives both Gs/cAMP and Gq/PLC; ORG-43902 activates cAMP robustly while suppressing LH-induced PLC [@vanKoppenSignalingSelectiveNanomolar2008]. The steroidogenic cascade runs through cAMP: PKA → StAR → cholesterol translocation into mitochondria → pregnenolone → testosterone. PLC does something different: β-arrestin recruitment, receptor internalization, and the progressive desensitization that makes chronic hCG use increasingly ineffective. hCG’s 24-36h half-life locks in that PLC-driven downregulation. ORG-43902’s t½ of 17-22h [@gerritsFirstEvidenceOvulation2013] and PLC-sparing profile should produce less Leydig cell desensitization for equivalent steroidogenic output, though this hasn’t been tested in Leydig cells directly.
Phase I data: 159 pituitary-suppressed women, single doses 30-300mg, 82-83% ovulation induction at 300mg, Tmax 0.5-1h, t½ 17-22h [@gerritsFirstEvidenceOvulation2013]. Clean safety signal. Oral bioavailability confirmed. What this doesn’t give you is any data on male Leydig cell function, intratesticular testosterone dynamics, or HPG feedback in men.
TSHR off-target activity exists: EC50 ~7.7μM vs LHCGR ~200nM in vitro, a 40-fold margin. Thyroid stimulation at typical doses is unlikely but worth a thyroid panel if dosing aggressively.
Practical advantages over hCG: no injection, no cold chain, no protein batch variability, and a biased signaling profile that should preserve Leydig cell responsiveness better over sustained use. The dose translation problem is the real gap: 300mg for ovulation induction in women is not a male Leydig cell dose. Community use runs 50-200mg empirically.
ORG-43553 is the better-characterized probe in this series, with 3.4nM cAMP EC50 vs ~200nM for ORG-43902, and is the compound van Koppen et al. used to map the allosteric site [@vanKoppenSignalingSelectiveNanomolar2008]. ORG-43902 is the clinical candidate; ORG-43553 is where the mechanistic literature is.